Data / Drug companies / HK Kolmar Canada, Inc
HK Kolmar Canada, Inc: 37 products in the FDA NDC directory, labeler code 49354
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
HK Kolmar Canada, Inc (labeler code 49354) lists 37 products in the FDA National Drug Code Directory, covering 2 finished drugs by generic name. By type: 32 drugs for further processing, 3 bulk ingredients. Its main marketing category is drugs for further processing. The newest product started marketing on July 1, 2024.
The request: Watch HK Kolmar Canada, Inc (FDA labeler code 49354): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 49354
- Products in commercial distribution
- 37
- Packages
- 37
- Finished drugs by generic name
- 2
- Prescription products
- 0
- Over the counter products
- 2
- Flagged as original packager
- 2 of 2 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- March 15, 2017
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 32 | 86.5% |
| Bulk ingredients | 2 | 5.4% |
| Over the counter monograph drugs | 2 | 5.4% |
| Bulk ingredients for compounding | 1 | 2.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 32 | 86.5% |
| Bulk ingredients | 3 | 8.1% |
| Over the counter drugs | 2 | 5.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Salicylic acid | 1 | 330 |
| Benzalkonium chloride | 1 | 271 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Lotion | 25 | 67.6% |
| Gel | 4 | 10.8% |
| Cream | 2 | 5.4% |
| Aerosol, foam | 2 | 5.4% |
| Suspension | 1 | 2.7% |
| Solution/ drops | 1 | 2.7% |
| Oil | 1 | 2.7% |
| Kit | 1 | 2.7% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Zinc oxide | 49354-167 | Lotion | Bulk ingredients | July 1, 2024 |
| Zinc oxide | 49354-166 | Lotion | Bulk ingredients | July 1, 2024 |
| Titanium dioxide, zinc oxide | 49354-161 | Lotion | Bulk ingredients for compounding | June 1, 2024 |
| Compound W Total Care Wart and Skin Kit | 49354-130 | Kit | Over the counter monograph drugs | December 5, 2022 |
| Avobenzone, homosalate, octisalate, octocrylene | 49354-126 | Oil | Drugs for further processing | December 15, 2021 |
| Zinc oxide | 49354-122 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-121 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-120 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-119 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-118 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-117 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-116 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-115 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-114 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-113 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-112 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-111 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-110 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-109 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-108 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-107 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-106 | Lotion | Drugs for further processing | September 1, 2021 |
| Zinc oxide | 49354-105 | Lotion | Drugs for further processing | September 1, 2021 |
| Titanium dioxide, zinc oxide | 49354-084 | Lotion | Drugs for further processing | March 15, 2021 |
| Titanium dioxide, zinc oxide | 49354-083 | Lotion | Drugs for further processing | March 15, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.